FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2018/03/012502 [Registered on: 12/03/2018] Trial Registered Retrospectively
Last Modified On: 10/03/2018
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   a clinical study to determine efficacy of proteolytic enzymes in dental surgery 
Scientific Title of Study   A prospective, double blind, randomized study evaluating the efficacy of systemically administered combination of proteolytic enzymes in third molar surgery: A clinical study. 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Trupti Gandhewar 
Designation  Additional Associate Professor 
Affiliation  Nair Hospital Dental College 
Address  Dept of Oral and Maxillofacial Surgery , Nair Hospital Dental College, Mumbai Central, Mumbai
Dr. A.Y.L Nair Road, Mumbai Central
Mumbai
MAHARASHTRA
400008
India 
Phone  9819323729  
Fax    
Email  tgandhewar@yahoo.com  
 
Details of Contact Person
Scientific Query
 
Name  trupti gandhewar 
Designation  Additional Associate Professor 
Affiliation  Nair Hospital Dental College 
Address  Dept of Oral and Maxillofacial Surgery , Nair Hospital Dental College, Mumbai Central Mumbai

Mumbai
MAHARASHTRA
400008
India 
Phone  9819323729  
Fax    
Email  tgandhewar@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Trupti Gandhewar 
Designation  additional associate professor 
Affiliation  Nair Hospital Dental College 
Address  Dept of Oral and Maxillofacial Surgery , Nair Hospital Dental College, Mumbai Central Mumbai

Mumbai
MAHARASHTRA
400008
India 
Phone  9819323729  
Fax    
Email  tgandhewar@yahoo.com  
 
Source of Monetary or Material Support  
Self Sponsored- Dr. Trupti Gandhewar, Nair Hsopital DEntal College, Mumbai Central, Mumbai, Maharashtra 
 
Primary Sponsor  
Name  Nair Hospital Dental College 
Address  Dr. A.L. Nair Road opp. Maratha Mandir Mumbai Central Mumbai- 400008 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Trupti Gandhewar  NAIR HOSPITAL DENTAL COLLEGE  Dr. AL Nair Road opp. Maratha Mandir Mumbai Central Maharashtra
Mumbai
MAHARASHTRA 
9819323729

tgandhewar@yahoo.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional ethics comiitee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  Patients Requiring Surgical Removal of impacted third molar Under Local Anesthesia on an out patient basis will be included in the trial,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Fixed Dose Combination of Trypsin , Bromelain and Rutoside  Trypsin – 48mg Bromelain – 90mg Rutoside – 100 mg Regimen: one hour before meals every 8 hours or thrice a day  
Comparator Agent  Timings of Administration of Fixed Dose combination of Trypsin, Bromelain and Rutoside  According to the group allocated, timing of administration of the same drug will be studied for its effect on pain and Swelling after Third Molar Study.  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  55.00 Year(s)
Gender  Both 
Details  1. Any patient with an partially impacted mandibular third molars (upto Level B, as per the Pell and Gregory scales) and indicated for its surgical extraction.
2. Any patient who willingly gives consent for the being involved in the study
3. Healthy adult patients in the age group of 18-40 years.
 
 
ExclusionCriteria 
Details  1. Pregnant females and Lactating mothers.
2. Patients who had/have any periapical or odontogenic lesion associated with the impacted tooth.
3. Patient known to be allergic to any constituent of the proteolytic drug combination.
4. Patients with a known allergy to co-amoxiclav group or NSAID drugs.
5. Patients with any underlying systemic condition/medication which will interfere with drug metabolism.
6. Patients on immunosuppresants.
7. Interincisal opening less than 3 cms.
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   An Open list of random numbers 
Blinding/Masking   Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded 
Primary Outcome  
Outcome  TimePoints 
Pain - VAS Score(Visual Analog Scale)
Swelling- Analytical assessment using Facial Measurements 
Day 0, Postoperative Day 1, Day 5 and Day 7 
 
Secondary Outcome  
Outcome  TimePoints 
Mouth Opening, Day of Work Attendance, Day of Resuming Eating, Number of Rescue Medications needed, Overall Discomfort  Pre op Day 0, Post op Day 1, Day 5 and Day 7 
 
Target Sample Size   Total Sample Size="200"
Sample Size from India="200" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   20/07/2016 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   none 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

AIM:

            The aim of the study is to determine the efficacy of systemically administered combination of proteolytic enzymes and their timings in third molar surgery.

 

OBJECTIVES:

 

1.    Evaluate efficacy of proteolytic enzymes used as a fixed dose combination in this study in terms of pain and swelling in the immediate post operative period.

 

2.    Evaluate whether any specific time for example before surgery or after surgery of administration of proteolytic enzymes changes the outcome and post opeartive sequelae. 

 

 

3.    Evaluate whether the outcome also changes when proteolytic enzymes are used concomitantly with non steroidal anti inflammatory drugs.

 

4.    Evaluate the quality of life of patients after third molar surgery with and without administration of proteolytic enzymes.

 

PATIENTS & METHOD:

 

Source of data:-

The patients will be selected from the OPD of the dept. of OMFS, NHDC, Mumbai, whose informed consent will be taken prior to the procedure. A maximum number of 200 patients with partially impacted mandibular third molars requiring surgical extraction will be selected.

 

 

Inclusion criteria:

1.   Any patient with an partially impacted mandibular third molars (upto Level B, as  per the Pell and Gregory scales) and indicated for its surgical extraction.

2.   Any patient who willingly gives consent for the being involved in the study

3.   Healthy adult patients in the age group of 18-40 years.

 

 

 

 

Exclusion criteria:

1.    Pregnant females and Lactating mothers.

2.    Patients who had/have any periapical or odontogenic lesion associated with the impacted tooth.

3.    Patient known to be allergic to any constituent of the proteolytic drug combination.

4.    Patients with a known allergy to co-amoxiclav group or NSAID drugs.

5.    Patients with any underlying systemic condition/medication which will interfere with drug metabolism.

6.    Patients on immunosuppresants.

7.    Interincisal opening less than 3 cms.

PROCEDURE:

Patients will be selected from OPD of NHDC, Mumbai. Detailed case history will be taken. Pre- operative medical & radiographic investigations will be done & informed consent will be taken.

All patients who are willing to participate in the study and are fit as per the inclusion criteria will be consecutively recruited in the study. However, the distribution of a particular patient into a particular group will be done on a random basis. The patients will be randomly divided into the four groups using a randomisation generator from http://www.randomization.com/ that randomizes each subject into single treatment by using the method of randomly permuted blocks

Total Number of patients – 200

Number of operating surgeons – 1

Patients will be randomly divided in four groups (50 patients in each group). All partially impacted mandibular third molars (upto Level B as per Pell and Gregory Scales) requiring surgical extraction presenting to the OPD will be selected for the study.

After obtaining informed consent from the patient for the surgical procedure patients will be kept blind about the group they are placed in. Operator who performs the surgery is blind to the group that the patient is allotted in, observer is blind to the medicines that the patient has received.

Patients will be sent for preoperative assessment of Hemoglobin, bleeding and clotting time and an intraoral periapical radiograph of the impacted mandibular third molar (if IOPA is not feasible then a lateral oblique view of the mandible will be taken).

Antibiotics having action over gram positive organisms (Amoxycillin 500mg three times a day) and NSAID’s (Diclofenac 50 mg and Paracetamol 500mg three times per day) available on the MCGM supply register will be provided to the patient as per his group/subgroup; if there is shortage of the same then the investigators shall bore the cost of the same.

 

Group  ( Half an Hour Before meals)

I – Antibiotics7 + Proteolyitc enzymes (started 48 hrs prior to surgery and continued for 3 days post surgery)

 

II – Antibiotics + Proteolyitc enzymes (started on the day of surgery and continued for 5 days post surgery)

 

III – Antibiotics + Proteolyitc enzymes (started immediately after surgery and continued for 5 days post surgery)

IV – Antibiotics + Proteolyitc enzymes + NSAID’s1 (started 6 hours after surgery and continued as a 5 day post surgery regimen)

 

 

 

 

Clinical Parameters:

 

1.    Proteolytic enzymes will be started 48 hours before surgery and continued 72 hours post surgery in group 1.

2.    In group III and IV no preoperative therapy will be initiated and it will be given only postoperatively. The first dose of the drug will be given immediately after the surgery in group III and continued thereafter for next 5 days at an eight hourly interval.

3.    Pain will be evaluated by Visual Analog Scale on 1st day, 5th day, 7­th day after surgery. Use of analgesic will be recorded.

4.    Facial swelling will be evaluated by measuring distance between 6 predetermined points on 1st day, 5th day, 7­th day after surgery. The points will be Canthus (Cn) to Gnathion (Gn), corner of the mouth (Cm) to tragus of the ear (Tr) and Pogonion (Pg) to tragus (Tr).

5.    Post operative quality of life of the patients will be evaluated on the basis of a questionnaire which is prepared and patients will be asked to fill it up on 7th post-op day.

6.    Any other complications related to the surgery/lesion will be recorded.

 
Close